Cohance Lifesciences Ltd (COHANCE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003386,
    "name": "Cohance Life",
    "stock_name": "Cohance Life",
    "full_name": "Cohance Lifesciences Ltd",
    "name_url": "stocks-analysis/cohance-life",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "415.55",
    "chg": -10.3,
    "chgp": "-2.42%",
    "dir": -1,
    "prev_price": "425.85",
    "mcapval": "15,897.58 Cr",
    "mcap": "Small Cap",
    "scripcode": 543064,
    "symbol": "COHANCE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE03QK01018",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "11.94 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/cohance-life-1003386-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-hits-intraday-high-with-757-surge-on-19-may-2026-3998541",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_priceRelatedfactors_3998541.png",
        "date": "2026-05-19 09:32:00",
        "description": "The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals &amp; Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend."
      },
      {
        "title": "Are Cohance Lifesciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-cohance-lifesciences-ltd-latest-results-good-or-bad-3989988",
        "imagepath": "",
        "date": "2026-05-13 19:21:48",
        "description": "Cohance Lifesciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a consolidated net profit of ₹19.55 crores, reflecting a substantial year-on-year decline of 83.77%. Net sales also experienced a notable contraction, decreasing by 26.33% year-on-year to ₹619.12 crores. This marks the fourth consecutive quarter of negative year-on-year growth, indicating a troubling trend in revenue generation.\n\nOperating margins have compressed significantly, falling to 15.94% from 27.27% in the previous year, which suggests difficulties in cost management and pricing power. The profit before tax showed an 87.62% decline year-on-year, further exacerbated by an unusually high tax rate of 58.26%, which is well above the company's historical average. \n\nOn a sequential basis, there was a marginal improvement in sales, which rose by 13.69% from the previous quarter, a..."
      },
      {
        "title": "Cohance Lifesciences Ltd Opens 8.21% Lower in Sharp Gap Down as Technicals Point to Further Weakness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-opens-with-significant-gap-down-amid-market-concerns-3989037",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_gapdown_3989037.png",
        "date": "2026-05-13 09:40:32",
        "description": ""
      },
      {
        "title": "Cohance Lifesciences Gains 3.90%: 4 Key Factors Driving This Week's Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-gains-390-4-key-factors-driving-this-weeks-momentum-3983087",
        "imagepath": "",
        "date": "2026-05-09 12:02:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Week opens at Rs.469.95</p>\n                    <p><strong>5 May:</strong> Stock declines 3.27% amid moderate market dip</p>\n                    <p><strong>6 May:</strong> Intraday high surge to Rs.498.05 with 8.78% rally and heavy value trading</p>\n                    <p><strong>7 May:</strong> Continued gains with 0.82% rise and strong volume</p>\n                    <p><strong>8 May:</strong> Modest 0.70% gain amid mixed technical momentum</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.469.95</div></div>\n                    <div class=..."
      },
      {
        "title": "When is the next results date for Cohance Lifesciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-cohance-lifesciences-ltd-3980479",
        "imagepath": "",
        "date": "2026-05-07 23:17:14",
        "description": "Cohance Lifesciences Ltd is scheduled to declare its results on 12 May 2026...."
      },
      {
        "title": "Cohance Lifesciences Ltd Sees Surge in Value Trading Amid Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-sees-surge-in-value-trading-amid-sector-outperformance-3977434",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_most_active_equities_by_value_3977434.png",
        "date": "2026-05-06 10:00:27",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in trading activity on 6 May 2026, driven by high-value turnover and notable institutional interest. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite a recent downgrade in its mojo grade."
      },
      {
        "title": "Cohance Lifesciences Ltd Surges 8.78% to Day's High of Rs 498.05 — Outperforms Sector by 8.05 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-hits-intraday-high-with-strong-878-surge-3977263",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_priceRelatedfactors_3977263.png",
        "date": "2026-05-06 09:31:11",
        "description": "The Sensex gained a modest 0.52% on 6 May 2026, while Cohance Lifesciences Ltd surged 8.78%, reaching an intraday high of Rs 498.05. This 8.05-percentage-point outperformance over its Pharmaceuticals &amp; Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Signal Price Attractiveness Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-signal-price-attractiveness-challenges-3976748",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_valuationdot_3976748.png",
        "date": "2026-05-06 08:00:55",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, prompting a reassessment of its price attractiveness. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages raise questions about its investment appeal amid volatile market returns."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Signal Heightened Price Risk Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-signal-heightened-price-risk-amid-sector-comparisons-3967395",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/CohanceLifescie_valuationdot_3967395.png",
        "date": "2026-04-29 08:00:50",
        "description": "Cohance Lifesciences Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a sharp 14.2% surge in its share price on 29 Apr 2026, invites a detailed analysis of its price attractiveness relative to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 15,
    "sid": "1003386",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/cohance-lifesciences-1003386"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "02-Jun-2026",
      "details": "Investors Meet",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "30-May-2026",
      "details": "Annual Secretarial Compliance Report",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "25-May-2026",
      "details": "Investors Meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has declared <strong>100%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 25 Sep 20",
          "dt": "2020-09-25",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points

2026-05-19 09:32:00

The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend.

Are Cohance Lifesciences Ltd latest results good or bad?

2026-05-13 19:21:48

Cohance Lifesciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a consolidated net profit of ₹19.55 crores, reflecting a substantial year-on-year decline of 83.77%. Net sales also experienced a notable contraction, decreasing by 26.33% year-on-year to ₹619.12 crores. This marks the fourth consecutive quarter of negative year-on-year growth, indicating a troubling trend in revenue generation. Operating margins have compressed significantly, falling to 15.94% from 27.27% in the previous year, which suggests difficulties in cost management and pricing power. The profit before tax showed an 87.62% decline year-on-year, further exacerbated by an unusually high tax rate of 58.26%, which is well above the company's historical average. On a sequential basis, there was a marginal improvement in sales, which rose by 13.69% from the previous quarter, a...

Cohance Lifesciences Ltd Opens 8.21% Lower in Sharp Gap Down as Technicals Point to Further Weakness

2026-05-13 09:40:32

Cohance Lifesciences Gains 3.90%: 4 Key Factors Driving This Week's Momentum

2026-05-09 12:02:54

Key Events This Week 4 May: Week opens at Rs.469.95 5 May: Stock declines 3.27% amid moderate market dip 6 May: Intraday high surge to Rs.498.05 with 8.78% rally and heavy value trading 7 May: Continued gains with 0.82% rise and strong volume 8 May: Modest 0.70% gain amid mixed technical momentum Week OpenRs.469.95 <div class=...

When is the next results date for Cohance Lifesciences Ltd?

2026-05-07 23:17:14

Cohance Lifesciences Ltd is scheduled to declare its results on 12 May 2026....

Cohance Lifesciences Ltd Sees Surge in Value Trading Amid Sector Outperformance

2026-05-06 10:00:27

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in trading activity on 6 May 2026, driven by high-value turnover and notable institutional interest. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite a recent downgrade in its mojo grade.

Cohance Lifesciences Ltd Surges 8.78% to Day's High of Rs 498.05 — Outperforms Sector by 8.05 Percentage Points

2026-05-06 09:31:11

The Sensex gained a modest 0.52% on 6 May 2026, while Cohance Lifesciences Ltd surged 8.78%, reaching an intraday high of Rs 498.05. This 8.05-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.

Cohance Lifesciences Ltd Valuation Shifts Signal Price Attractiveness Challenges

2026-05-06 08:00:55

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, prompting a reassessment of its price attractiveness. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers and historical averages raise questions about its investment appeal amid volatile market returns.

Cohance Lifesciences Ltd Valuation Shifts Signal Heightened Price Risk Amid Sector Comparisons

2026-04-29 08:00:50

Cohance Lifesciences Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a sharp 14.2% surge in its share price on 29 Apr 2026, invites a detailed analysis of its price attractiveness relative to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

View All News